Amylyx Pharmaceuticals Inc AMLX

$28.57 -0.46 (-1.58%)

Valuation

Market cap
3,234,610,000
Revenue TTM
$0
Net income TTM
$-144,740,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
1,307,900
Avg volume
2,343,026
Day's range
$28.51 – $30.00
Shares out
111,423,000
Stochastic %K
62%
Beta
-0.10
Analysts
Strong Sell
Price target
$39.67

Price

Company profile

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsu...

Show more

Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
617 682 0917
Website
https://amylyx.com
Address
55 Cambridge Parkway, Suite 6W, Cambridge, United States

Latest news

Stocktwits

SilentBull69 Oct 23, 11:18 AM
$AMLX Looking for a Moderna type move with AMLX ✌️ As soon as we start moving forward with commercialization, I think that’s exactly what we’re gonna see 😎 And then we still have additional pipelines  moving in a positive direction  
0 replies
LoveRetailFroth Oct 22, 4:27 PM
$AMLX Soon 30,49,50,60….. 🚀
0 replies
LoveRetailFroth Oct 22, 1:57 PM
$AMLX Good Morning my bio 💎 s☕️ $RXRX $TSHA $SMMT 🏃‍♂️ to the EOY
0 replies
11thestate Oct 22, 12:58 PM
Investors can still file late claims for the $6.5M $AMLX settlement. If you bought Amylyx Pharmaceuticals ($AMLX) shares between 2022 and 2023, you actually have a chance to recover your losses: https://11th.com/cases/amylyx-pharmaceutical-investor-settlement
0 replies
Cryspi Oct 20, 7:43 PM
$AMLX volume is kind of 🔥🔥🔥
0 replies
SilentBull69 Oct 20, 4:26 PM
$AMLX Back up…✌️
0 replies
LoveRetailFroth Oct 20, 1:58 PM
$TSHA Good Morning ☕️ Stellar Bio. 💎s. $AMLX $RXRX $PRQR
0 replies
ajmore Oct 17, 7:53 AM
$AMLX Heres a table of ETFs holding Amylyx [in Desc order] (This is what I've been saying!) [Amylyx wss added to the select in mid september, a orecursor to addition to the S&P 400, once meets profits criteria which shoupd be very soo ):
1 replies